Dogwood Therapeutics (DWTX) Total Non-Current Liabilities (2024)
Dogwood Therapeutics (DWTX) posted quarterly Total Non-Current Liabilities of $14.6 million for Q4 2024.
Dogwood Therapeutics (DWTX) Total Non-Current Liabilities (2024) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Total Non-Current Liabilities for 1 consecutive years, with $14.6 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities changed N/A year-over-year to $14.6 million; the TTM figure through Dec 2024 stood at $14.6 million (changed N/A YoY), while the FY2024 annual figure was $14.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities was little changed at $14.6 million in Q4 2024 per DWTX's latest filing.
- Across five years, Total Non-Current Liabilities topped out at $14.6 million in Q4 2024 and bottomed at $14.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.65 Mn |